 Intravenous theanine injection suppresses nociceptive SpVc WDR neuronal excitability.
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Acute intravenous administration of dietary constituent theanine suppresses noxious neuronal transmission of trigeminal spinal nucleus caudalis in rats
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Introduction
The spinal trigeminal nucleus is an important relay station in transmitting orofacial sensory information and is functionally subdivided into three nuclei from rostral to caudal: oralis, interpolarlis, and caudalis (Sessle 1987) . In particular, the spinal trigeminal nucleus caudalis (SpVc) relays trigeminal nociceptive inputs from sites of inflammation and tissue injury (Sessle et al., 2000; Takeda et al., 2012) . Chronic pathological conditions such as tissue inflammation can change the properties of somatic sensory pathways, leading to hyperalgesia and allodynia (Scholz and Woolf 2002) , while changes in the excitability of primary afferent neurons (peripheral sensitization) alter information processing in the spinal trigeminal nucleus or higher centers (Millan 1999) . Previous studies have demonstrated that wide dynamic range (WDR) neurons in the SpVc region are important in the mechanism underlying hyperalgesia/allodynia and/or referred pain associated with orofacial pain (Takeda et al., 2000 (Takeda et al., , 2012 . Complementary and alternative medicine (CAM), such as herbal remedies and acupuncture, has been used clinically to treat persistent chronic pain (Rao 1999; Konvicka et al., 2008; Rosenberg et al., 2008) , and considerable research has focused on the potential effects of diet and dietary supplementation on conditions associated with pain (Shir et al., 2001; Ernest et al., 2003; Tall and Raja 2004) . We recently showed that intravenous administration of dietary resveratrol suppresses nociceptive SpVc WDR neuronal activity via the glutaminergic excitatory synaptic transmission of SpVc by inhibiting postsynaptic glutamate receptors . Also, local injection of resveratrol into the peripheral receptive field suppresses the excitability of SpVc WDR neurons, possibly via inhibition of voltage-gated Na + channels in the nociceptive nerve terminal of trigeminal ganglion neurons . In addition, choronic administration of resveratrol has been shown to attenuate inflammation-induced nociceptive SpVc WDR neuronal excitability associated with hyperalgesia via inhibition of both peripheral and central cyclooxygenase-2 cascade signaling pathways . Together, 4 these findings support the idea that dietary constituents such as resveratrol could be potential therapeutic CAM for the alleviation of nociceptive pain and prevention of trigeminal inflammatory hyperalgesia.
Theanine (γ-glutamylethylamide) is an amino acid derivate of glutamic acid found almost exclusively in certain teas. Theanine extracts from green tea have been suggested to prevent and cure cancer via intrinsic biological activity (Weiner et al., 2009) . Theanine is structurally similar to glutamic acid, a primary excitatory neurotransmitter in the central nervous system (Nathan et al., 2006) , and can bind to glutamate receptors, α-amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid (AMPA), kainite, and N-methyl-Daspartate (NMDA) receptors (Kakuda et al., 2002; Maruyama and Takeda 1994) . Hence, theanine acts as a natural antagonist of glutamate in synaptic neurotransmission (Shinozaki and Ishida 1978: Kakuda et al., 2002) . Since it has been demonstrated that blockade of glutamatergic transmission via NMDA and non-NMDA receptors results in significant inhibition of excitatory neurotransmission of SpVc, glutamatergic transmission mechanisms in the SpVc have clinical importance for primary headache syndromes, such as migraine and cluster headache (Storer and Goadsby 1999) . Cahn and MaassenVanDenBrink (2014) indicated that glutamate receptor antagonists play an important role in the management to migraine. Intraperitoneal injection of theanine into mice also elevated the intracerebral level of γ-aminobutyric acid (GABA) within 30 min, suggesting that theanine is transported into the brain through the blood-brain barrier and can alter intracerebral GABA levels (Kimura et a., 1971; Egashira et al., 2007) . These findings suggest that theanine could modulate excitatory and inhibitory neuronal transmission in the central nervous system. Based on these observations, we hypothesized that theanine administration would attenuate noxious stimulation-induced excitability of SpVc neuronal activity through a central mechanism, as is the case for local anesthetic agents and/or analgesic drugs, it could be a candidate CAM for pain. However, the acute effects of theanine on trigeminal neuronal activity in vivo in response to nociceptive and non-nociceptive mechanical stimulation remain to be determined. Therefore, the present study investigated whether acute intravenous administration of theanine to rats could attenuate the excitability of nociceptive SpVc WDR neuronal activity in vivo in response 5 to mechanical stimulation.
Material and methods
The experiments described herein were approved by the Animal Use and Care Committee of Azabu University and were performed in accordance with the guidelines of the International Association for the Study of Pain (Zimmerman, 1983) . Every effort was made to minimize the number of animals used and their suffering.
Extracellular single unit recording of WDR neuronal activity in the SpVc
Electrophysiological recordings were made in 13 adult male Wistar rats weighing 230-290 g. Rats were anesthetized with pentobarbital sodium (45 mg/kg, i.p.) and anesthesia was maintained with additional doses of 2-3 mg/kg per h pentobarbital sodium through a cannula into the jugular vein, as required. The level of anesthesia was confirmed by the absence of corneal reflex and lack of response to paw pinching. Rectal temperature was maintained at 37.0 ± 0.5C with a homeothermic blanket during recording. Rats were placed in a stereotaxic apparatus, and the activity of a single neuron from the SpVC region was recorded extracellularly. Single neuron activity was recorded using a glass micropipette filled with 2% pontamine sky blue and 0.5 M sodium acetate according to the stereotaxic coordinates of Paxinos and Watson (1986) . Neuronal activity was amplified (DAM 80; World Precision Instruments), filtered (0.3-10 kHz), monitored with an oscilloscope (SS-7672; Iwatsu, Tokyo, Japan), and then recorded on a polygraph (NEC-Sanei 8M14) for subsequent off-line analysis using PowerLab and Chart 5 software (ADInstruments, Oxford, UK).
In some experiments (n = 5), the single neuron activity was instead recorded using a three-barreled glass micropipette filled with 2% pontamine sky blue and 0.5 M sodium acetate as described in our previous studies (Takeda et al., 2000 , with iontophoretic application as described in our previous reports (Takeda et al., 2000 (Takeda et al., , 2005c Tanimoto et al. 2004) . Of the two lateral barrels of the micropipette, one barrel containing 160 mM NaCl was used for balancing currents to prevent the occurrence of tip polarization 6 artifacts. The remaining barrel contained L-glutamate (100 mM in 160 mM NaCl, pH 8.5; Nacalai Tesque, Kyoto, Japan), as described previously (Takeda et al., , 2008 . The currents for ejecting, retaining, and balancing were provided by a constant current unit (Dia Medical, DPI-25, Japan). The drugs were ejected with 10-90 nA cationic currents, and 10-25 nA retaining currents were used.
Animal experiment protocols
Extracellular recordings of SpVc WDR unit activity were made as follows.
Mechanical stimulation was used to identify the receptive field quickly and to avoid sensitizing peripheral receptors. In this way, we identified single units that responded to stimulation on the left side of the orofacial facial skin (whisker pad) with a brush and a set of von Frey hairs (Semmes-Weinstein Monofilaments; North Coast Medical, Gilroy, CA, USA). Noxious pinch stimulation, which evoked a pain sensation when applied to a human subject, was applied to the orofacial area of rats using forceps. After identification of WDR SpVc neurons responding to stimulation of the whisker pad, we checked for spontaneous discharge. The threshold for mechanical stimulation was determined using non-noxious and noxious mechanical stimulation (5 s) with von Frey hairs (1, 2, 4, 6, 10, 15, 26, 60 g) at 5-sec intervals. The mechanical receptive field of neurons was mapped by probing the facial skin with von Frey hairs, and then outlined on a life-sized drawing of a rat on tracing paper. The WDR neuronal discharges induced by mechanical stimulation were quantified by subtracting background activity from evoked activity, and spontaneous discharge frequencies were determined over 2-5 min. If no discharge was recorded, the cell was deemed a silent neuron. The mean firing rate of SpVc WDR neurons evoked by mechanical stimulation was compared before and after drug administration. Since previous studies have demonstrated the importance of WDR neurons in the SpVc region in the mechanism underlying hyperalgesia and referred pain associated with orofacial pain (Takeda et al., 2000 (Takeda et al., ,2012 , the present study focused on the effects of theanine on SpVc WDR neuronal activity, although we did not examine nociceptive-specific neurons (Ness and Randich 2006). Post-stimulus histograms (bin =
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The effects of theanine (10, 50, and 100mM, i.v.) , injected through a cannula into the jugular vein, were evaluated 5, 10, 20, and 30 min after administration when peak effect and recovery are thought to occur. Theanine was dissolved in saline, and the stock solution was stored at -20℃ in small aliquots until use. The mean spontaneous and mechanical stimulation-induced discharges rates, as well as the mechanical threshold before and after intravenous administration of theanine, were evaluated in the present study.
Identification of recording sites
Recording sites of SpVc WDR neuronal activity were identified as described previously (Takeda et al., 2000 (Takeda et al., , 2012 . Briefly, at the end of the recording sessions, rats were deeply anesthetized and anodal DC currents (30 μA, 5 min) were passed through a recording micropipette. The rats were then perfused transcardially with saline and 10%
formalin. Frozen coronal sections (30 μm) were cut and stained with hematoxylin-eosin.
Recording sites were identified from the blue spots, and the path of electrode tracks was constructed in combination with the micromanipulator readings.
Data analysis
Values are expressed as the mean ± SEM. Statistical analyses were performed using two-way repeated-measures analysis of variance (ANOVA) followed by Tukey-Kramer or Dunnett's post hoc tests for electrophysiological data. P < 0.05 was considered significant.
Results
General properties of SpVc WDR neurons innervating facial skin
Extracellular single unit activity recorded from 15 neurons in the SpVc, responding to non-noxious and noxious mechanical stimulation, exhibited a somatic receptive field in the orofacial area (mainly whisker pad; Fig.1A ), as described previously Sekiguchi et al., 2016; Takeda et al., 2000) . Every neuron recorded belonged to the WDR category Sekiguchi et al., 2016; Takeda et al., 2012) .
Two of the 15 units exhibited spontaneous discharges. As shown in Fig. 1B , recording sites were found in layers I-III (n = 6; 40%) and IV-V (n = 9; 60%) of the SpVc (obex from -0.5 to -2 mm). Fig. 1C shows typical examples of SpVc WDR neuronal unit responses. Graded mechanical stimulation was applied to the most sensitive area of the receptive field, which exhibited increased a firing frequency of SpVc WDR neurons in proportion to the stimulus intensity. The mean mechanical stimulation-induced spike threshold was 2.8 ± 1.3 g (n = 15). or in the mechanical threshold after theanine administration. SpVc WDR neuronal activity evoked by non-noxious mechanical stimulation is summarized in Figure 3 . After theanine injection, there was a significant decrease in the mean firing rate of non-noxious mechanical stimulation-evoked SpVc WDR neuronal activity, which eventually returned to control levels (before theanine injection). Mean firing rates before and after theanine were 13.5 ± 2.8 vs. 5.0 ± 1.5 Hz, respectively, in response to the 6-g stimulus and 20.1 ± 3.1 vs. 9.5 ± 2.3 Hz, respectively, in response to the 10-g stimulus (n = 5, P < 0.05 for both). As indicated in Figure 4 , The suppression of SpVc WDR neuronal firing in response to non-noxious stimulation was significantly greater following intravenous injection of 10 vs. 100 mM theanine (10.5 ± 8.1% vs. 35.6 ± 5.4%, respectively, for the 6-g stimulus; 14.4 ± 6.0% vs. 38.1± 4.9%, respectively, for the 10-g stimulus (n = 5, P < 0.05 for all; Fig. 4 ). Noxious (15-60 g) mechanical stimulation-evoked SpVc WDR neuronal activity was inhibited 5 min after the injection of theanine, and again this inhibition disappeared within approximately 10 min, with activity returning to control levels. Similarly, SpVc WDR neuronal activity in response to noxious pinch stimulation was inhibited 5 min after the theanine injection, and then returned to control levels (before theanine injection). within 10 min.
Effects of intravenous administration of theanine on excitability of SpVc WDR neurons in response to non-noxious stimuli
As indicated in Figure 3 , the mean firing rates of SpVc WDR neurons evoked by noxious mechanical and pinch stimulation decreased significantly after injection of theanine compared with (before theanine injection) : 49.0 ± 7.5 vs. 23.9 ± 4.7 Hz, respectively, for the 26-g stimulus; 57.6 ± 2.9 vs. 27.3 ± 4.7 Hz, respectively, for the 60-g stimulus; and 68.7 ± 5.4 vs 34.4 ± 2.2 Hz, respectively, for the pinch stimulus (n = 5, P < 0.05 for all). The suppression of SpVc WDR neuronal firing in response to noxious mechanical and pinch stimulation was significantly greater following intravenous injection of 10 vs. 100 mM theanine (16.9 ± 6.4% vs. 45.4 ± 8.4, respectively, for the 26-g stimulus; 20.2 ± 3.6% vs. 50.2 ± 5.9%, respectively, for the 60-g stimulus; and 22.3 ± 10.6% vs. 52.9 ± 6.5%, respectively, for the pinch stimulus (n = 5, P < 0.05 for all; Fig.   3 ). No significant changes were observed in the mean receptive field size after theanine administration (before vs after 14.5 ± 0.1 mm 2 vs. 15.9 ± 0.3 mm 2 , n = 5, NS). There were also no changes in the spontaneous firing rate after theanine administration. Intravenous administration of vehicle had no significant effect on either spontaneous or evoked (nonnoxious, noxious mechanical, and pinch stimulation) activity of SpVc WDR neurons (n = 3; Fig. 2 ).
SpVc WDR neuronal activity in response to noxious vs. non-noxious stimuli after theanine
As shown in Figure 5 , we also compared the relative inhibitory effect of 100 mM i.v.
theanine on responses to non-noxious and noxious stimuli. The mean magnitude of inhibition by theanine of SpVc WDR neuronal discharge frequency was significantly greater for noxious than non-noxious stimuli (35.8 ± 3.4% vs. 49.0 ± 4.6%, respectively; n = 13, P < 0.05).
Iontophoretic application of L-glutamate-evoked neuronal discharge frequency of SpVc WDR neurons responding to noxious mechanical stimulation
In this study we found that five of the SpVc WDR neurons responding to noxious mechanical stimulation of the whisker pad were also activated by iontophoretic application of glutamate (Fig. 6 ). As shown in Fig. 6A , we observed that these neurons were also activated by iontophoretic application of glutamate, as previously described (Takeda et al., , 2008 , and that the glutamate-evoked discharge was reproducible across the 5-sec intervals (Fig. 2B) . The firing frequency of iontophoretic glutamate application-evoked spike frequency was current-dependently increased (30, 50, and 70 nA), as were the mean discharge frequencies of SpVc WDR neuronal activity evoked by iontophoretic glutamate application ( Fig. 6B ; n = 5). There were no significant differences in mean discharge frequency between noxious stimulations (60 g) and iontophoretic application of glutamate (50 nA; Fig. 6B ). We also observed that iontophoretic application of vehicle (160 mM, NaCl pH 4.5) had no significant effect on the SpVc WDR spinal neuronal activity, as previous described (n = 3, data not shown; Takeda et al., 2008) . Figure 7 shows the effect of intravenously administered theanine on the iontophoretic application of glutamate-evoked SpVC WDR neuronal activity responding to noxious stimulation. Glutamate-evoked discharges of SpVc WDR were inhibited in a reversible manner (Fig. 7A) , and the mean firing frequency of these neurons responding to vs. 97.8 ± 7.9 Hz, n = 5, P < 0.05, Fig. 7B ). These inhibitory effects were reversed within approximately 10 min.
Suppression of iontophoretic application of glutamate-evoked neuronal discharge frequency after intravenous theanine administration
Discussion
This study provides the first evidence that acute intravenous theanine administration suppresses glutaminergic excitatory synaptic transmission in the SpVc. These findings suggest that dietary constituent, theanine, could have potential as a CAM therapeutic agent for trigeminal nociceptive pain.
Intravenous acute administration of theanine suppresses excitability of SpVc
WDR neurons
Our main study findings are as follows: (i) mean SpVc WDR neuronal firing rate was dose-dependently inhibited by theanine (1-100 mM, i.v.) in response to both non-noxious and noxious mechanical stimuli; (ii) this discharge inhibition was reversible within approximately 10 min; (iii) intravenous administration of vehicle had no significant effect on either the spontaneous or evoked (non-noxious, noxious mechanical, and pinch stimulation) activity of SpVc WDR neurons. Theanine is known to pass through the blood-brain barrier via a leucine-preferring transport system (Yokogoshi et al., 1998) .
Following the systemic administration of 100 mM theanine in the present study, the drug was detected in the bloodstream to a calculated concentration of approximately 1 mM, and this concentration still had a significant effect on the nociceptive transmission of SpVc firing. In crayfish, 1 mM theanine also significantly inhibited glutaminergic excitation at the neuromuscular junction (Shinozaki and Ishida 1978) . Together, these findings suggest that under in vivo conditions, acute intravenous theanine administration suppresses trigeminal nociceptive transmission in the SpVc
Mechanism underlying the suppression of nociceptive glutaminergic synaptic transmission by theanine
Several previous findings indicate that theanine can modulate excitatory and inhibitory neuronal transmission in the central nervous system (Kimura et a., 1971; Egashira et al., 2007; Kakuda et al., 2002; Maruyama and Takeda 1994; Shinozaki and Ishida 1978) , including elevation of intracerebral GABA levels within 30 min of intraperitoneal theanine administration that suggested transport into the brain through the blood-brain barrier (Kimura et a., 1971; Egashira et al., 2007) . In this study we found that theanine-induced inhibition of the discharge frequency of SpVc WDR neurons in response to both non-noxious and noxious mechanical stimuli was reversible and occurred within approximately 10 min. Considering the different time course of theanine effectiveness between previous studies and the experimental findings presented herein, it is reasonable to speculate that the inhibitory effect of nociceptive and non-nociceptive transmission evoked by acute theanine administration may not happen via a GABAergic mechanism. Our finding of no significant change in receptive field size before and after theanine administration supports such a speculation, particularly in light of a previous study indicating that a local GABAergic mechanism in the SpVc modulates the mechanical receptive field properties (Takeda et al., 2000) . Clearly, further studies are needed to identify the precise inhibitory mechanism at play with nociceptive transmission in the presence of theanine.
Interestingly, theanine binds to glutamate receptors, AMPA, kainite, and NMDA receptors (Kakuda et al., 2002; Maruyama and Takeda 1994) , and a previous study demonstrated that iontophoretically applied glutamate induced the amplitude of excitatory junctional potentials was reversible inhibited by theanine, implicating theanine as a glutamate antagonist (Shinozaki and Ishida 1978) . Di et al., (2010) also reported that theanine attenuates L-glutamate-induced apoptosis via NMDA receptor-related signaling pathways. In the present study, we found that (i) the relative magnitude of inhibition by theanine of SpVc WDR neuronal discharge frequency was significantly greater for noxious than non-noxious stimulation; (ii) the mean firing frequency of SpVc WDR neurons responding to iontophoretic application of glutamate was inhibited by 13 intravenous administration of theanine; (iii) there was no significant difference in mean discharge frequency between noxious mechanical stimulation (60 g) and iontophoretic application of glutamate (50 nA); and, (iv) the mean firing frequency of SpVc WDR neurons responding to iontophoretic application of 50-nA glutamate was significantly inhibited by intravenous administration of theanine, with the maximal inhibition of discharge frequency observed by 5 min and reversed within 10 min. Taken together, our findings suggest that acute intravenous theanine administration suppresses the glutaminergic excitatory post synaptic transmission, possibly via an NMDA receptor signaling pathways in the SpVc convergence inputs from noxious rather than nonnonxious sensory information. However, further studies are needed to elucidate the mechanistic basis of the speculations.
Functional significance of suppressing nociceptive glutaminergic synaptic transmission by theanine
The SpVc nucleus is an important relay station for trigeminal nociception, including for the orofacial region. Thus, because SpVc WDR neurons contribute to hyperalgesia and/or referred pain associated with dental pain (Takeda et al., 2000 (Takeda et al., , 2012 Nishikawa et al., 2004) , only the effect of theanine on SpVc WDR neuronal activity was evaluated in the present study and nociceptive-specific neurons were not tested.
Following injury and inflammation of the neural tissue innervating the orofacial area, changes in the properties of these neurons lead to pathological pain, such as hyperalgesia and allodynia (Iwata et al., 1999; Takeda et al., 2012) . In addition, we reported previously that temporomandibular joint inflammation-induced hyperexcitability of SpVc WDR neurons contributes to the ectopic mechanical allodynia innervating facial skin (Takeda et al., , 2012 . Previous our study showed that there is a convergence of sensory inputs from the superior sagittal sinus (SSS) and tooth pulp afferent on the the first cervical dorsal horn (C1) neurons, and NMDA and non-NMDA receptors located in the C1 neurons contributes to the mechanism of trigeminal referred pain associated with migraine (Fujimi et al., 1999) . Storer and Goadsby (1999) has been demonstrated that blockade of glutamatergic transmission via NMDA and non-NMDA receptors results in 14 significant inhibition of excitatory neurotransmission of SpVc. Since trigeminovascular nociceptive fibers are activated by the functionally specific stimulation of the SSS, it is likely that glutamatergic transmission has trigeminal transmission in acute primary headache syndromes, such as migraine and cluster headache (Storer and Goadsby 1999) .
Cahn and MaassenVanDenBrink (2014) indicated that glutamate receptor antagonists play an important role in the management to migraine. Actually, it has been known that kynurenic acid is an endogenous glutamate receptor blocker, a potent NMDA receptor antagonist (Birch et al., 1988) . Casáti et al (2015) recently reported that administration of kynurenic acid resulted in the inhibition of inflammation-induced activation of neuronal signaling system in the trigeminal ganglia. Thus, our present study suggests that acute theanine administration could indeed attenuate the excitability of SpVc WDR neurons associated with the trigeminal area and tissue injury/inflammation, including migraine and cluster headache .
It is also known that patients frequently turn to CAM therapies such as herbal medicines and acupuncture for pain control when other medical treatments are ineffective (Konvicka et al., 2008; Rosenberg et al., 2008) . Consequently, the potential influence of diet and dietary supplementation on conditions associated with pain have been the focus of considerable research (Shir et al., 2001; Tall et al., 2001; Rivat et al., 2008) , and increasing CAM agents are being developed for the treatment of persistent chronic pain (Rosenberg et al., 2008; Kessler et al., 2001) . The safety of theanine is important when considering its potential clinical applications. To this end, theanine administered in a dietary mixture to rats for 13 weeks produced no adverse effects even at a dose of 4000 mg/Kg/day (Borzelleca et al., 2006) . In addition, Tarumizu et al., (2015) reported recently that a compound health supplement containing theanine provided some relief for patients with low back pain, suggesting that theanine could be a safe alternative or complement to non-steroidal anti-inflammatory drugs therapy for conditions such a lower back pain.
Because incisions associated with surgery cause acute pain and surgery has been identified as a potential major cause of chronic pain (Perkins and Kehlet 2000; Kehlet et al., 2006) , it can be speculated that theanine may effectively reduce clinical pain, such as postoperative pain (Locher-Claus et al., 2005; Tillu et al., 2012) . Taken together, the 15 results of the preset study support the idea that dietary constituents theanine could be a part of an effective CAM strategy for alleviating nociceptive pain and preventing trigeminal inflammatory hyperalgesia. and at 5 and 10 min after theanine intravenous administration. *, P < 0.05, n = 5, before vs. after 100 mM, i.v. theanine administration. # , P < 0.05, n=5, 30 nA vs 50nA, 70nA.
Figure legends
